Colchicine After Electrocardioversion for Atrial Fibrillation
Recruiting
Phase 3
Interventional Study
Atrial Fibrillation
Cardiac Arrhythmia
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 416 (estimated)
- Sponsor
- University Hospital, Basel, Switzerland · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age \>18 years
* ECG-documented AF prior to ECV
* Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV
* Ability to give written informed consent
Exclusion Criteria:
* AF persistence after cardioversion or early AF recurr…
Contacts